# Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm

> **NCT05027997** · PHASE2 · COMPLETED · sponsor: **Addex Pharma S.A.** · enrollment: 15 (actual)

## Conditions studied

- Blepharospasm
- Dystonia

## Interventions

- **DRUG:** Dipraglurant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05027997
- **Lead sponsor:** Addex Pharma S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2022-10-27
- **Final completion:** 2022-11-27
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027997, "Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05027997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*